Mult Scler. 2007 Jun;13(5):567-77. Epub 2007 Feb 16.

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.

Source

Department of Neuroimmunology, Institute of Neurology, London, UK.

Abstract

Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS.

PMID:: 17548434; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? [Mult Scler. 2007]
Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS, Koch-Henriksen N, Bendtzen K. Mult Scler. 2007 Jun; 13(5):616-21. Epub 2007 Feb 9.
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. [Mult Scler. 2009]
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. Mult Scler. 2009 May; 15(5):601-5. Epub 2009 Mar 19.
Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. [Neurol Sci. 2005]
Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S, Capobianco M, Gilli F, Marnetto F, Caldano M, Sala A, Bertolotto A. Neurol Sci. 2005 Dec; 26 Suppl 4:S213-4.
Review Neutralizing antibodies to multiple sclerosis treatments. [J Manag Care Pharm. 2004]
Review Neutralizing antibodies to multiple sclerosis treatments.
Rossman HS. J Manag Care Pharm. 2004 Jun; 10(3 Suppl B):S12-9.
Review Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. [J Neurol Sci. 2008]
Review Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
Hurwitz BJ. J Neurol Sci. 2008 Sep 15; 272(1-2):8-19. Epub 2008 Jul 11.

See reviews... See all...

Cited by 2 PubMed Central articles

Neutralizing antibodies against interferon-Beta. [Ther Adv Neurol Disord. 2008]
Neutralizing antibodies against interferon-Beta.
Sorensen PS. Ther Adv Neurol Disord. 2008 Sep; 1(2):62-78.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. [Ther Clin Risk Manag. 2010]
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Johnson KP. Ther Clin Risk Manag. 2010 Apr 15; 6:153-72. Epub 2010 Apr 15.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Measuring and management of anti-interferon beta antibodies in subjects with mul...
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Mult Scler. 2007 Jun ;13(5):567-77. Epub 2007 Feb 16 .

PubMed
Antipsychotic drug use and mortality in older adults with dementia.
Antipsychotic drug use and mortality in older adults with dementia.
Ann Intern Med. 2007 Jun 5 ;146(11):775-86.

PubMed
Clinical trial registration: looking back and moving ahead.
Clinical trial registration: looking back and moving ahead.
Ann Intern Med. 2007 Aug 21 ;147(4):275-7. Epub 2007 Jun 4 .

PubMed
The re-emergence in Canada of meningovascular syphilis: 2 patients with headache...
The re-emergence in Canada of meningovascular syphilis: 2 patients with headache and stroke.
CMAJ. 2007 Jun 5 ;176(12):1699-700.

PubMed
Duplex ultrasonography, magnetic resonance angiography, and computed tomography ...
Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review.
BMJ. 2007 Jun 16 ;334(7606):1257. Epub 2007 Jun 4 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: